Mizuho Forecasts Strong Price Appreciation for Pediatrix Medical Group (NYSE:MD) Stock

Pediatrix Medical Group (NYSE:MD) had its target price lifted by investment analysts at Mizuho from $13.00 to $15.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Mizuho’s target price would indicate a potential upside of 3.59% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the company. UBS Group lifted their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Jefferies Financial Group lifted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a report on Wednesday, November 13th. Truist Financial boosted their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Price Performance

Shares of NYSE MD opened at $14.48 on Tuesday. The firm’s 50-day simple moving average is $12.61 and its 200 day simple moving average is $9.89. The stock has a market cap of $1.24 billion, a P/E ratio of -4.73, a P/E/G ratio of 2.03 and a beta of 1.55. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. Pediatrix Medical Group has a fifty-two week low of $6.62 and a fifty-two week high of $16.41.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The company had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. Pediatrix Medical Group’s revenue was up .9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.29 EPS. Equities analysts expect that Pediatrix Medical Group will post 1.25 EPS for the current year.

Insiders Place Their Bets

In other news, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the transaction, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. The trade was a 18.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO James D. Swift sold 11,100 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the sale, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. This represents a 6.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 53,808 shares of company stock worth $751,277 over the last ninety days. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

Several institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in shares of Pediatrix Medical Group by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company’s stock worth $22,452,000 after purchasing an additional 45,155 shares during the period. M&T Bank Corp lifted its position in Pediatrix Medical Group by 20.1% in the 3rd quarter. M&T Bank Corp now owns 85,264 shares of the company’s stock worth $988,000 after buying an additional 14,247 shares in the last quarter. Barclays PLC boosted its stake in shares of Pediatrix Medical Group by 302.9% during the 3rd quarter. Barclays PLC now owns 142,087 shares of the company’s stock valued at $1,646,000 after buying an additional 106,817 shares during the period. Jane Street Group LLC grew its holdings in shares of Pediatrix Medical Group by 54.0% during the 3rd quarter. Jane Street Group LLC now owns 303,283 shares of the company’s stock valued at $3,515,000 after acquiring an additional 106,332 shares in the last quarter. Finally, Weiss Asset Management LP grew its holdings in shares of Pediatrix Medical Group by 50.5% during the 3rd quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock valued at $10,580,000 after acquiring an additional 306,143 shares in the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.